Comparison of two genetically distant type 2 porcine reproductive and respiratory syndrome virus (PRRSV) modified live vaccines against Vietnamese highly pathogenic PRRSV

Tien, Duy; Park, Changhoon; Choi, Kyuhyung; Jeong, Jiwoon; Nguyen, Teron; Nguyen, Khang Duong; Vo, Dai Tan; Chae, Chanhee

doi:10.1016/j.vetmic.2015.06.013

Cited by 23 publications

(14 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, none of the neutralizing antibody was detected within 3 weeks after challenge in this study. In the several previous studies, even though MLV could not induce neutralizing antibodies in the sera, MLV could confer cross-protection against heterologous challenge (Do et al 2015;Li et al 2014;Park et al 2015). Our results were similar to previous studies involving challenge with heterologous PRRSV in vaccinated pigs, and logistically revealed that humoral immunity was not a major contributor to the early protection.…”

Section: Discussionsupporting

confidence: 90%

“…However, the IFN-γ recalling response is not able to completely reflect the complicated nature of cell-mediated immunity. There are still other immunological mechanisms, such as IL-10 cytokine modulation and T helper polarization, that might participate in the host defense against PRRSV and play roles in vaccine-induced immune protections (Do et al 2015;Kick et al 2019;Liu et al 2016;Lunney et al 2016;Park et al 2015;Park et al 2014).…”

Section: Discussionmentioning

confidence: 99%

“…This MLV vaccine was derived from a US PRRSV isolate (P129) that was sequentially attenuated in a porcine-originated cell line, rather than other species. To the best of our knowledge, it has been proven that Fostera PRRS can elicit immunogenicity and broad cross-protection against lineages 1, 5, 8 and 9 of type II and even type I PRRSV (Calvert et al 2017;Choi et al 2016;Do et al 2015;Park et al 2015;Park et al 2014;Savard et al 2016). However, there is very little information regarding the cross-protection of commercial vaccines against lineage 3 of type II PRRSV so far.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Peer Review #1 of "Evaluation of a type 2 modified live porcine reproductive and respiratory syndrome vaccine against heterologous challenge of a lineage 3 highly virulent isolate in pigs (v0.1)"

Mickaël¹

2020

View full text Add to dashboard Cite

Porcine reproductive and respiratory syndrome (PRRS) is one of the most common diseases in the global swine industry. PRRSV is characterized by rapid mutation rates and extensive genetic divergences. It is divided into two genotypes, which are composed of several distinct sub-lineages. The purpose of the present study was to evaluate the crossprotective efficacy of Fostera PRRS MLV, an attenuated lineage 8 strain, against the heterologous challenge of a lineage 3 isolate. Eighteen pigs were randomly divided into mock, MLV and unvaccinated (UnV) groups. The pigs in the MLV group were administered Fostera PRRS vaccine at 3 weeks of age and both the MLV and UnV groups were inoculated with a virulent PRRSV isolate at 7 weeks. Clinically, the MLV group showed a shorter duration and a lower magnitude of respiratory distress than the UnV group. The average days of fever in the MLV group was 3.0±0.5, which was significantly lower than the 6.2±0.5 days of the UnV group (P<0.001). The average daily weight gains of the mock, MLV and UnV groups were 781±31, 550±44 and 405±26 g/day, respectively, during the post-challenge phase. The pathological examinations revealed that the severity of interstitial pneumonia in the MLV group was milder compared to the UnV group. Furthermore, PRRSV viremia titers in the MLV pigs were consistently lower (10 1-10 1.5 genomic copies) than those of the UnV pigs from 4 to 14 DPC. In conclusion, vaccination with Fostera PRRS MLV confers partial cross-protection against heterologous challenge of a virulent lineage 3 PRRSV isolate.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Peer Review #1 of "Evaluation of a type 2 modified live porcine reproductive and respiratory syndrome vaccine against heterologous challenge of a lineage 3 highly virulent isolate in pigs (v0.1)"

Mickaël¹

2020

View full text Add to dashboard Cite

show abstract

“…So far, vaccines have been the most effective tool in controlling HP-PRRSV infection. Commercial PRRS modified-live virus vaccines have been reported as effective against HP-PRRSV [ 4 , 11 ]. However, no study has reported the efficacy of commercial PRRS subunit vaccines.…”

mentioning

confidence: 99%

Comparative evaluation of the efficacy of commercial and prototype PRRS subunit vaccines against an HP-PRRSV challenge

Duy

Kim

Jeong

et al. 2018

The Journal of Veterinary Medical Science

Self Cite

View full text Add to dashboard Cite

The objective of this study was to compare the efficacy of a commercial porcine reproductive and respiratory syndrome (PRRS) subunit vaccine and a prototype PRRS II subunit vaccine against a highly pathogenic PRRS virus (HP-PRRSV) in pigs. Both vaccines were administered intramuscularly in 2 doses at 21 and 42 days of age, and the pigs were challenged intranasally with HP-PRRSV at 63 days of age. Pigs vaccinated with the prototype PRRS II subunit vaccine had significantly higher anti-PRRSV antibody titers, a greater number of interferon-γ-secreting cells, and a greater reduction in lung lesion scores compared to pigs vaccinated with the commercial PRRS subunit vaccine. Therefore, the commercial PRRS subunit and prototype PRRS II subunit vaccines are efficacious against HP-PRRSV.

show abstract

“…Currently, some modified live PRRSV vaccines are available. However, they offer protection against homologous strains, but are inconsistent and offer incomplete protection against heterologous strains [5], which requires constant vaccine developments.…”

mentioning

confidence: 99%

Heterologous expression of porcine reproductive and respiratory syndrome virus glycoprotein 5 in <i>Bordetella bronchiseptica</i><i>aroA</i> mutant

Park

Seo

Kim

2016

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

Porcine reproductive and respiratory syndrome virus (PRRSV) is an economically important disease around the globe. Protection against this virus remains problematic. Here, we evaluated antibody (IgG & IgA) inducibility of a heterologous PRRSV glycoprotein 5 (GP5) expressed in a live attenuated Bordetella bronchisepticaaroA mutant strain (BBS-GP5). Mice and pigs were primed with recombinant GP5 (rGP5) subcutaneously followed by boosting with live BBS-GP5. As a result, anti-GP5 IgG was induced in both mice (P<0.001) and pigs (P<0.1). Pigs were challenged with live PRRSV (VR2332). Viral RNA was found to be significantly (P<0.01) removed in the vaccinated pig group. Overall, BBS-GP5 is a good candidate as a live attenuated vaccine against PRRSV infection.

show abstract

Comparison of two genetically distant type 2 porcine reproductive and respiratory syndrome virus (PRRSV) modified live vaccines against Vietnamese highly pathogenic PRRSV

Cited by 23 publications

References 38 publications

Peer Review #1 of "Evaluation of a type 2 modified live porcine reproductive and respiratory syndrome vaccine against heterologous challenge of a lineage 3 highly virulent isolate in pigs (v0.1)"

Peer Review #1 of "Evaluation of a type 2 modified live porcine reproductive and respiratory syndrome vaccine against heterologous challenge of a lineage 3 highly virulent isolate in pigs (v0.1)"

Comparative evaluation of the efficacy of commercial and prototype PRRS subunit vaccines against an HP-PRRSV challenge

Heterologous expression of porcine reproductive and respiratory syndrome virus glycoprotein 5 in <i>Bordetella bronchiseptica</i><i>aroA</i> mutant

Contact Info

Product

Resources

About